Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential upside of 8.0% according to Berenberg Bank.
Berenberg Bank set a target price of 2,000 GBX for the company, which when compared to the Hikma Pharmaceuticals Plc share price of 1,852 GBX at opening today (07/03/2024) indicates a potential upside of 8.0%. Trading has ranged between 1,615 (52 week low) and 2,222 (52 week high) with an average of 410,650 shares exchanging hands daily. The market capitalisation at the time of writing is £4,133,957,135.
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio. Its subsidiaries include Al Jazeera Pharmaceutical Industry S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others.
Hikma Pharmaceuticals Plc 8.0% potential upside indicated by Berenberg Bank
- Written by: Charlotte Edwards
Latest Company News
Ahead of its Annual General Meeting, Hikma said all three businesses are performing well, announced a device partnership to support its generic Ellipta programme, and confirmed its 2026 revenue and profit guidance remains unchanged.
FTSE 100 falls midday as Smiths Group and Legal & General lead declines while Hikma Pharmaceuticals and BP provide support.
Hikma achieved 6% core revenue growth and maintained resilient margins in 2025, supported by strong Branded and Hikma Rx performance. The company outlined a cautious 2026 outlook, leadership changes, a 5% dividend increase, and a $250 million share buyback programme.
Hikma Pharmaceuticals has announced that Riad Mishlawi has stepped down as Chief Executive Officer and as a board member by mutual agreement.
Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales. Core operating profit declined 7% due to product mix and prior-year comparators, but the company expects a stronger H2.
Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and strategic position.
